Baylor University Medical Center
Pulmonary and Critical Care fellowship · Dallas, TX · Program website
This program's roster hasn't been collected yet, so there's no list of its own faculty and papers. Below is Baylor University Medical Center's research in pulmonary and critical care, which the program shares with other departments and affiliated hospitals.
About Baylor University Medical Centerinstitution-wide pulmonary and critical care research
Pulmonary and Critical Care publications from Baylor University Medical Center and affiliated institutions, since 2022. Updated 2026-11-06; refreshed daily.
30
works per year
66th of 79 pulmonary and critical care fellowship programs
+12.3%
2-year growth
38th of 79 pulmonary and critical care fellowship programs
27.0%
in top 10% of field (works before 2025)
13th of 74 pulmonary and critical care fellowship programs
39.3%
cited above world average
43rd of 74 pulmonary and critical care fellowship programs
Works per year · * 2026 so far
Pulmonary and Respiratory Medicine · 151Critical Care and Intensive Care Medicine · 9
Pulmonary and Critical Care research topics at Baylor University Medical Center
Papers in the window; each links to the list on OpenAlex.
- Advanced Breast Cancer Therapies 29
- Aortic Disease and Treatment Approaches 20
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis 12
- Neonatal Respiratory Health Research 11
- Sarcoma Diagnosis and Treatment 10
- Lung Cancer Treatments and Mutations 10
- Vascular Procedures and Complications 7
- Vasculitis and related conditions 6
Most cited at Baylor University Medical Center since 2024
All pulmonary and critical care papers there on OpenAlex
- Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2− advanced breast cancer: final overall survival results of MONARCH 3Matthew Philip Goetz et al. · Annals of Oncology · 2024 · PubMed · cited 248
- Meaningful Endpoints for Idiopathic Pulmonary Fibrosis (IPF) Clinical Trials: Emphasis on ‘Feels, Functions, Survives’. Report of a Collaborative Discussion in a Symposium with Direct Engagement from Representatives of Patients, Investigators, the National Institutes of Health, a Patient Advocacy Organization, and a Regulatory AgencyGanesh Raghu et al. · American Journal of Respiratory and Critical Care Medicine · 2024 · PubMed · cited 98
- Overall survival with abemaciclib in early breast cancerStephen R.D. Johnston et al. · Annals of Oncology · 2025 · PubMed · cited 78
- Activity and safety of enobosarm, a novel, oral, selective androgen receptor modulator, in androgen receptor-positive, oestrogen receptor-positive, and HER2-negative advanced breast cancer (Study G200802): a randomised, open-label, multicentre, multinational, parallel design, phase 2 trialCarlo Palmieri et al. · The Lancet Oncology · 2024 · PubMed · cited 50
- Imlunestrant with or without abemaciclib in advanced breast cancer: updated efficacy results from the phase III EMBER-3 trialKomal L. Jhaveri et al. · Annals of Oncology · 2025 · PubMed · cited 37
- International Liver Transplantation Society practice guideline update on portopulmonary hypertensionHilary M. DuBrock et al. · Liver Transplantation · 2025 · PubMed · cited 31
- Early real-world experience monitoring circulating tumor DNA in resected early-stage non–small cell lung cancerTravis K. Martin et al. · Journal of Thoracic and Cardiovascular Surgery · 2024 · PubMed · cited 23
- Clinical outcomes and ctDNA correlates for CAPOX BETR: a phase II trial of capecitabine, oxaliplatin, bevacizumab, trastuzumab in previously untreated advanced HER2+ gastroesophageal adenocarcinomaHarshabad Singh et al. · Nature Communications · 2024 · PubMed · cited 22
- Intensive Care Unit Sleep Promotion Bundle: Impact on Sleep Quality, Delirium, and Other Patient OutcomesNicole M. Gorecki et al. · Critical Care Nurse · 2024 · PubMed · cited 17
- MET (c-Met) protein overexpression is an emerging protein biomarker in non-small cell lung cancerMing‐Sound Tsao et al. · npj Precision Oncology · 2025 · PubMed · cited 15